최소 단어 이상 선택하여야 합니다.
최대 10 단어까지만 선택 가능합니다.
다음과 같은 기능을 한번의 로그인으로 사용 할 수 있습니다.
NTIS 바로가기Urology, v.56 no.6, 2000년, pp.1063 - 1067
Schröder, Annette (Department of Urology, Johannes Gutenberg-University, Mainz, Germany) , Levin, Robert M (Albany Medical College, Albany, New York, USA) , Kogan, Barry A (Albany Medical College, Albany, New York, USA) , Das, Anurag K (Albany Medical College, Albany, New York, USA) , Kay, Francine (FEI Enterprises Ltd, Plainsboro, New Jersey, USA) , Mahashabde, Anu (FEI Enterprises Ltd, Plainsboro, New Jersey, USA)
AbstractObjectives. Oxybutynin has been used for treatment of urge urinary incontinence for more than 20 years. However, one of the major problems with its use is uncomfortable anticholinergic side effects that can lead to discontinuation of treatment. Alternative forms of drug administration may re...
Steers 142 1994 Campbell’s Urology Physiology of the urinary bladder
Zderic SA, Levin RM, and Wein AJ: Voiding function and dysfunction: a relevant anatomy, physiology, pharmacology, and molecular biology, in Gillenwater JY, Grayhack JT, Howards SS, et al (Eds): Adult and Pediatric Urology, 3rd ed. Chicago, Mosby-Year Book, 1996, pp 1159-1219.
Scand J Urol Nephrol Levin 30 suppl 15 1996 Etiology of incontinence
Urology Hampel 50 4 1997 10.1016/S0090-4295(97)00578-5 Definition of overactive bladder and epidemiology of urinary incontinence
J Pharmacol Exp Ther Levin 212 536 1980 Cholinergic, adrenergic, and purinergic response of sequential strips of rabbit urinary bladder
Clin Ther Goldenberg 21 634 1999 10.1016/S0149-2918(00)88316-2 An extended-release formulation of oxybutynin chloride for the treatment of overactive urinary bladder
J Urol Anderson 161 1809 1999 10.1016/S0022-5347(05)68810-6 Once daily controlled versus immediate release oxybutynin chloride for urge urinary incontinence
J Clin Pharmacol Gupta 39 289 1999 10.1177/009127009903900313 Pharmacokinetics of an oral once-a-day controlled-release oxybutynin formulation compared with immediate-release oxybutynin
Clin Pharmacol Ther Gupta 65 672 1999 10.1016/S0009-9236(99)90089-9 Quantitative characterization of therapeutic index
J Urol Thüroff 145 813 1991 10.1016/S0022-5347(17)38459-8 Randomized double-blind, multicenter trial on treatment of frequency, urgency and incontinence related to detrusor hyperactivity
J Urol Levin 128 396 1982 10.1016/S0022-5347(17)52944-4 Direct measurement of the anticholinergic activity of a series of pharmacological compounds on the canine and rabbit urinary bladder
Urology Wein 51 suppl 2A 43 1998 10.1016/S0090-4295(98)90009-7 Pharmacologic options for the overactive bladder
J Urol Buyse 160 892 1998 10.1016/S0022-5347(01)62828-3 Intravesical oxybutynin for neurogenic bladder dysfunction
J Urol Massad 148 595 1992 10.1016/S0022-5347(17)36663-6 The pharmacokinetics of intravesical and oral oxybutynin chloride
Urology Pannek 55 358 2000 10.1016/S0090-4295(99)00540-3 Combined intravesical and oral oxybutynin chloride in adult patients with spinal cord injury
Drug Metab Dispos Kocarek 23 415 1995 Comparative analysis of cytochrome P4503A induction in primary cultures of rat, rabbit and human hepatocytes
Eur J Obstet Gynecol Reprod Biol Barentsen 71 73 1997 10.1016/S0301-2115(96)02612-7 Continuous low dose estradiol released from a vaginal ring versus estriol vaginal cream for urogenital atrophy
Am J Obstet Gynecol Henriksson 174 85 1996 10.1016/S0002-9378(96)70378-2 A one-year multicenter study of efficacy and safety of a continuous, low-dose, estradiol-releasing vaginal ring (Estring) in postmenopausal women with symptoms and signs of urogenital aging
*원문 PDF 파일 및 링크정보가 존재하지 않을 경우 KISTI DDS 시스템에서 제공하는 원문복사서비스를 사용할 수 있습니다.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.